Medicines & Healthcare products Regulatory Agency

10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom
gov.uk/mhra

7 March 2024

Dear [redacted]

FOI 24/148

Thank you for your information request dated 12 February 2024 where you asked:

1. *Please could you provide data on when pharmaceutical manufacturers removed the side effect of autism from the manufacturers leaflet.*

2. *If it is not within the MHRAs remit to work out what causes autism and what effects aluminium and glyphosate play a part in this, then who is responsible within the UK?*

3. *Regarding DTAP, what data do you collect regarding the below in comparison to no vaccination given*

    a. *Data on pregnancy outcome after the vaccination of DTAP and also COVID*
    b. *Data on the placenta condition after the vaccination of DTAP and also covid*
    c. *Data on the fetus outcome after vaccination of DTAP and also covid, ie birth, miscarriage, still birth, within 6 months of delivery of vaccination*

We can confirm that the MHRA does not hold the information requested.

It is unclear which product you are referring to in your first question, however autism has never been included as a possible side effect in the product information for any vaccine authorised by the MHRA.

For your second question, this is not within the remit of the MHRA. To assist, you may wish to view The National Autistic Society and University of Cambridge websites for further information on research:

https://www.autism.org.uk/advice-and-guidance/what-is-autism/the-causes-of-autism

https://www.clara.psychol.cam.ac.uk/

In relation to your third question, the MHRA does not collect the data mentioned above after either DTAP or COVID vaccination in comparison to no vaccination given. The MHRA collects reports of spontaneous suspected adverse reactions via the Yellow Card Scheme.

If you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of this response; and can be addressed to this email address.

Yours sincerely,

FOI Team,

If you have a query about this email, please contact us. If you are unhappy with our decision, you may ask for it to be reviewed. That review will be undertaken by a senior member of the agency who has not previously been involved in your request. If you wish to pursue that option, please write to the Communications Directorate, 4-T, Medicines and Healthcare products Regulatory Agency (via this email address). After that, if you remain dissatisfied, you may ask the Information Commissioner at:

The Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF